Skip to main content
SCI logo

SCI — Investor Relations & Filings

Ticker · 4119 ISIN · TW0004119003 TW Manufacturing
Open in API
Filings indexed 1,697 across all filing types
Latest filing 2022-02-14 Director's Dealing
Country TW Taiwan
Listing TW 4119

About SCI

www.sci-pharmtech.com.tw

SCI Pharmtech, Inc. specializes in the research, development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and specialty chemicals. Established in 1987 and originally founded by the Swiss Siegfried Group, the company provides high-quality chemical solutions and custom manufacturing services to leading global pharmaceutical corporations across Europe, North America, and Japan. Its core operations encompass advanced chemical synthesis, process optimization, and large-scale production within GMP-compliant facilities. With a robust R&D infrastructure including specialized laboratories and pilot plants, the company delivers technical excellence in complex chemical processing. SCI Pharmtech maintains a strong focus on quality assurance and international regulatory compliance, positioning itself as a reliable partner for the global healthcare and life sciences sectors.

Recent filings

Filing Released Lang Actions
111年01月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed tabulation of shareholdings by insiders and related parties of the company 旭富製藥科技股份有限公司. It lists positions such as Chairman, Vice Chairman, Directors, Independent Directors, General Manager, Deputy General Managers, Managers, and other key personnel along with their shareholdings, pledged shares, and related information. The document does not contain financial statements, earnings data, or management discussion of financial results. It is focused on insider shareholdings and their changes, which aligns with reporting insider transactions or holdings by directors and executives. Given the content and the nature of the data, this document fits the category of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). The document length is 3147 characters, which is consistent with a detailed insider shareholding report rather than a full financial report or announcement. Therefore, the classification is DIRS with high confidence.
2022-02-14 Chinese
111年1月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a brief financial disclosure from a listed company (旭富) providing information about fund loans and endorsement guarantees for the current and previous month, with amounts all zero. It is a short, factual regulatory disclosure without detailed financial statements or analysis. The document length is only 601 characters, indicating it is a short announcement rather than a full report. There is no indication of an annual or interim report, audit report, or other detailed filings. This type of document fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2022-02-09 Chinese
111年1月營業收入
Fund Information / Factsheet Classification · 90% confidence The document is a summarized financial data report showing monthly and cumulative net operating revenue figures for a company named 旭富 for the period 民國111年01月 (January 2022). It includes percentage changes and explanations for revenue changes due to operational impacts (fire damage). The document is very short (786 characters) and primarily provides a brief financial summary without detailed financial statements or analysis. It does not represent a full financial report like an Annual Report (10-K) or Interim Report (IR). It is also not an announcement of a report publication or a regulatory filing. Given the concise nature and focus on key financial facts, this fits best as a Fund Information / Factsheet (FS) type document, which is a brief summary of key company financials and market info.
2022-02-09 Chinese
公告本公司與銀行簽訂中期放款合約。
Capital/Financing Update Classification · 100% confidence The document is a short announcement (769 characters) about the company signing a medium-term loan agreement with a bank, including details about the loan amount, collateral, and purpose. It does not contain financial statements or detailed financial analysis. It is an update on financing activity, specifically a loan agreement, which fits the Capital/Financing Update category. The document is not a full report, nor an announcement of a report publication, nor a certification. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2022-01-26 Chinese
公告本公司高流動性資產、短期借款、應付短期票券及 一年內到期之長期負債。
Regulatory Filings Classification · 95% confidence The document is a short announcement (785 characters) providing specific financial data about the company's high liquidity assets, short-term borrowings, short-term notes payable, and long-term liabilities due within one year as of December 2021. It references a regulatory clause and a specific date of occurrence. There is no indication of a full financial report, management discussion, or detailed analysis. The document is a regulatory disclosure of financial information but does not contain comprehensive financial statements or detailed report content. It fits best as a Regulatory Filing (RNS) because it is a compliance disclosure of financial data without being a full report or announcement of a report publication.
2022-01-20 Chinese
110年12月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed tabulation of shareholdings by insiders and related parties of the company 旭富製藥科技股份有限公司. It lists share counts held by directors, managers, and other insiders, including pledged shares and shares held by spouses or minors. The document is focused on insider shareholdings and does not contain financial statements, earnings data, or management discussion. It is not a report or announcement of financial results, nor a regulatory filing about voting or dividends. The content matches the definition of a Director's Dealing report, which involves reporting personal share transactions or holdings by company directors and executives. The document length is 3147 characters, which is consistent with a detailed insider shareholding report rather than a brief announcement or a full financial report. Therefore, the appropriate classification is Director's Dealing (DIRS).
2022-01-12 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.